Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736931 | 1.00 | ALDH1A1 (0.32) | ALDH1A1POLB | |
| SCHEMBL28099919 | 0.91 | — | — | |
| SCHEMBL968359 | 0.80 | CHRM2 (0.31) | ALDH1A1POLB | |
| SCHEMBL17015170 | 0.77 | — | — | |
| SCHEMBL967469 | 0.77 | — | — | |
| SCHEMBL9160217 | 0.77 | — | — | |
| SCHEMBL10557059 | 0.75 | — | — | |
| Clorethate SCHEMBL41346 | 0.75 | CHRM2 (0.39) | ALDH1A1POLB | |
| SCHEMBL9230930 | 0.75 | ALDH1A1 (0.34) | ALDH1A1POLB | |
| SCHEMBL41347 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025070241-A1 | COMPOUND OR SALT THEREOF, AND METHOD FOR PRODUCING THE SAME | 藤本化学製品株式会社 | 2025-04-03 | — | — | WO | claimed |
| US-11339131-B2 | Process for preparing elagolix sodium and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2022-05-24 | — | — | US | claimed |
| WO-2025070241-A1 | COMPOUND OR SALT THEREOF, AND METHOD FOR PRODUCING THE SAME | 藤本化学製品株式会社 | 2025-04-03 | — | — | WO | disclosed |
| EP-4031533-B1 | PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2025-01-01 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023127855-A1 | CYCLOPENTENONE DERIVATIVE AND METHOD FOR PRODUCING SAME | 大内新興化学工業株式会社 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023276983-A1 | SYNTHESIS INTERMEDIATE FOR BERAPROST OR OPTICALLY ACTIVE FORM THEREOF, AND METHOD FOR PRODUCING SAME | 大内新興化学工業株式会社 | 2023-01-05 | — | — | WO | disclosed |
| US-11339131-B2 | Process for preparing elagolix sodium and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2022-05-24 | — | — | US | disclosed |
| WO-2021054896-A1 | PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2021-03-25 | — | — | WO | disclosed |
| US-20210078956-A1 | PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2021-03-18 | — | — | US | disclosed |
| EP-3345893-B1 | UREA DERIVATIVE AND USE THEREFOR | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-6344570-B1 | ANTISTICKING AGENTS FOR CELLS | ASTRAZENECA UK LIMITED (GB) | 2002-02-05 | — | — | US | disclosed |
| EP-1100492-A4 | INDOLE sPLA 2? INHIBITORS | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1100492-A1 | INDOLE sPLA 2? INHIBITORS | Eli Lilly & Company (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6235925-B1 | RING CLOSURE METHATHESIS AND NOBLE METAL CATALYSTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-22 | — | — | US | disclosed |
| EP-1030835-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000007590-A1 | INDOLE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999024398-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339131-B2 | Process for preparing elagolix sodium and intermediates thereof | OGG1, ELP1, UNG | ALDH1A1 254/4885POLB 40/4885 |
| US-20210078956-A1 | PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF | OGG1, ELP1, UNG | ALDH1A1 254/4885POLB 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.